Compare Ascendis Pharma A/S (ASND) vs NetApp Inc. (NTAP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs NetApp Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while NetApp Inc. trades at $167.59 (market cap $33.08B). The key difference: NetApp Inc. is the larger of the two by market cap, and NetApp Inc. pays a 1.23% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | NTAP | |
|---|---|---|
Market Cap | $17.74B | $33.08B |
Sector | Health | Technology |
52-Week High | $277.18 | $181.08 |
52-Week Low | $163.32 | $94.11 |
Enterprise Value | $18.11B | $32.23B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
NetApp (NTAP) trades at $168.87, down 1.67% on the day but up significantly year-to-date, driven by strong AI infrastructure demand. The stock shows bullish technical signals with moving averages aligned positively, while fundamentals reveal robust profitability with an 18.43% net margin and consistent earnings beats. Recent news highlights partnerships and AI workload enhancements, supporting growth momentum.
Outlook remains positive with AI-driven revenue acceleration, though valuation multiples like P/E of 26.59 suggest premium pricing. Risks include competitive pressures and execution challenges in scaling AI offerings. Analyst consensus leans hold with a $167.45 target, indicating limited near-term upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About NetApp Inc.
NetApp is a leading provider of enterprise data management and storage solutions. The company's three operating business units are products, software maintenance, and hardware maintenance. NetApp transitioned from a data center storage firm to a company with software data management solutions for multicloud environments. The California-headquartered company sells globally and has approximately 10,000 employees.
Read more on NTAP →
